Business
TriSalus Reports Q2 2024 Financial Results and Business Update
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\n\nReported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods\n\n\n\n\nReported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods\n\n\n\n\nAnnounces plan to launch the “DELIVER” Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System (TriNav) in complex patient types and aiming to significantly expand the addressable market\n\n\n\n\nExpects to report data from phase 1 trials of nelitolimod in uveal melanoma liver metastases and locally advanced pancreatic cancer via its pancreatic infusion technology in Q4 2024\n\n\n\n\nFollowing demonstrated tolerability and efficacy in a limited number of patients in the checkpoint doublet cohort studying nelitolimod in hepatocellular cancer and intrahepatic cholangiocarcinoma (PERIO-2), Company intends to proceed with only investigator-initiated studies in combination with regionally delivered chemotherapy or radiation embolic therapies\n\n\n\n\nClosed up to $50 million of debt financing with OrbiMed to support the TriNav system growth initiatives\n\n\n\n\nCompleted warrant exchange offer to simplify capital structure\n\n\n\n\nManagement to host earnings conference call on August 15th at 9:00 a.m. EDT\n\n\n\n DENVER--(BUSINESS WIRE)--\nTriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the second quarter ended June 30, 2024, and provided a business update.\n\n\nMary Szela, President and Chief Executive Officer of TriSalus Life Sciences, stated, \"We concluded the second quarter with robust revenue growth and effective execution across our operations. Our sustained revenue growth underscores the critical demand for our Pressure Enabled Drug Delivery™ technology (PEDD ™). We are excited to launch the DELIVER program, which will showcase the advantages of our TriNav system in treating a diverse array of complex patients.”\n\n\n“Additionally, we have successfully advanced development of nelitolimod, having treated 100 patients in four indications and three clinical trials using our PEDD technology. Our pro...